The Science and Business of Drug Discovery

Angebote / Angebote:

The Science and Business of Drug Discovery is written for those who want to learn about the biopharmaceutical industry and its products whatever their level of technical knowledge. Its aim is to demystify the jargon used in drug development, but in a way that avoids over simplification and the resulting loss of key information. Each of the nineteen chapters is illustrated with figures and tables which clarify some of the more technical points being made. Also included is a drug discovery case history which draws the relevant material together into a single chapter. In recognizing that it is difficult to navigate through the many external resources dealing with drug development, the book has been written to guide the reader towards the most appropriate information sources, including those listed in the two appendices. The following topics are covered:Different types of drugs: from small molecules to stem cellsBackground to chemistry of small and large moleculesHistorical background to drug discovery, pharmacology and biotechnologyThe drug discovery pipeline: from target discovery to marketed medicineCommercial aspects of drug discovery Challenges to the biopharmaceutical industry and its responsesMaterial of specific interest to technology transfer executives, recruiters and pharmaceutical translators  About the AuthorDr. Edward D. Zanders has over twenty years’ experience as a scientist and research manager in both a major pharmaceutical company and in smaller biotechnology organizations. He has been responsible for a number of drug discovery programs for diseases such as asthma and rheumatoid arthritis and has been involved in research management at a senior level. He has also published extensively on subjects ranging from biochemistry and immunology to computer-aided drug design, more recently he has written about the application of online networking to drug discovery. In 2004 he founded PharmaGuide Ltd, a training and consultancy company that delivers courses on the drug discovery industry to various professional groups including technology transfer executives, recruiters and technical translators. It is through delivering these courses that he has been able to develop his own way of conveying complex information about drug discovery to non scientists, while at the same time being able to communicate with PhD level scientists at their level of expertise.